의약품 수탁제조 및 조사 서비스 시장 규모, 점유율 및 동향 분석 보고서 : 서비스별, 지역별 및 부문별 예측(2026-2033년)

Pharmaceutical Contract Manufacturing And Research Services Market Summary

The global pharmaceutical contract manufacturing and research services market size was valued at USD 283.1 billion in 2025 and is projected to grow from USD 303.8 billion in 2026 to USD 472.1 billion by 2033, at a CAGR of 6.5% from 2026 to 2033. Asia Pacific dominated the market, accounting for the largest share of 42.3% in 2025. The pharmaceutical contract manufacturing and research services industry is anticipated to grow over the forecast period owing to increasing pharmaceutical and biotechnology outsourcing, rising research and development activities for biologics, biosimilars, and specialty drugs, growing demand for cost-efficient and flexible manufacturing, expanding clinical trial pipeline, and increasing investments in advanced manufacturing technologies and integrated CDMO and CRO capabilities.

The market growth is further supported by the need to reduce development timelines, manage complex regulatory requirements, and access specialized technical expertise without large capital investments. The growing focus on end-to-end outsourcing across drug discovery, development, and commercial manufacturing is strengthening demand for contract manufacturing and research service providers.

The increasing outsourcing of pharmaceutical development and manufacturing remains one of the primary growth drivers for the market. Pharmaceutical and biotechnology companies are increasingly partnering with contract service providers to reduce infrastructure costs, improve operational flexibility, and accelerate product development timelines. The growing complexity of biologics, cell and gene therapies, highly potent compounds, and personalized medicines has further increased the need for specialized manufacturing and research capabilities. The integrated service model offered by contract organizations enables sponsors to manage development and commercialization through a single partner while maintaining regulatory compliance and improving operational efficiency.

The expansion of manufacturing capacity and specialized capabilities across leading service providers is further supporting market growth. Companies continue to invest in advanced production technologies and high-value manufacturing infrastructure to address increasing outsourcing demand. For instance, in November 2024, Lonza announced the expansion of its bioconjugation capabilities at its Visp, Switzerland, facility by adding two 1,200 L manufacturing suites to support growing demand for complex therapeutics. The investment is expected to strengthen commercial manufacturing capacity for advanced pharmaceutical products and enhance integrated development and manufacturing services offered to global pharmaceutical and biotechnology companies. Market growth is moderated by stringent regulatory compliance requirements, high capital investment for advanced manufacturing facilities, and pricing pressure across outsourcing contracts. The increasing demand for biologics, specialty therapeutics, integrated development services, and the expansion of pharmaceutical outsourcing across emerging markets are expected to create significant opportunities for contract manufacturing and research service providers over the coming years. Overall, the increasing preference for outsourcing, expanding drug development pipelines, and continuous investments in specialized research and manufacturing capabilities are expected to support the long-term growth of the pharmaceutical contract manufacturing and research services market.

Global Pharmaceutical Contract Manufacturing And Research Services Market Report Segmentation

This report forecasts revenue growth at the global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global pharmaceutical contract manufacturing and research services market report based on service and region:

• Service Outlook (Revenue, USD Million, 2021 - 2033)
• Manufacturing
  • API/Bulk Drugs
  • Advanced Drug Delivery Formulations
  • Packaging
  • Finished Dose Formulations
  • Solid
  • Liquid
  • Semi-solid Formulations
• Research
  • Oncology
  • Vaccines
  • Inflammation & Immunology
  • Cardiology
  • Neuroscience
  • Others
• Regional Outlook (Revenue, USD Million, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • Thailand
  • South Korea
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • UAE
  • Saudi Arabia
  • Kuwait
  • Qatar
  • Oman

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Service
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Top-Down Analysis
  • 1.7.3. Bottom-Up Approach
  • 1.7.4. Multivariate Analysis
• 1.8. List Of Secondary Sources
• 1.9. List Of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Pharmaceutical Contract Manufacturing And Research Services Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
  • 3.2.3. Market Opportunity Analysis
  • 3.2.4. Market Challenge Analysis
• 3.3. Technology Landscape
• 3.4. Pricing Model Analysis
• 3.5. Tariff Impact Analysis
• 3.6. Market Analysis Tools
  • 3.6.1. Porter's Five Force Analysis
  • 3.6.2. PESTEL by SWOT Analysis

Chapter 4. Pharmaceutical Contract Manufacturing And Research Services Market: Service Estimates & Trend Analysis

• 4.1. Pharmaceutical Contract Manufacturing And Research Services Market, By Service: Segment Dashboard
• 4.2. Pharmaceutical Contract Manufacturing And Research Services Market, By Service: Movement Analysis
• 4.3. Pharmaceutical Contract Manufacturing And Research Services Market Estimates & Forecasts, By Service, 2021 - 2033 (USD Million)
• 4.4. Manufacturing
  • 4.4.1. Manufacturing Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.2. API/Bulk Drugs
    • 4.4.2.1. API/Bulk Drugs Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.3. Advanced Drug Delivery Formulations
    • 4.4.3.1. Advanced Drug Delivery Formulations Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.4. Packaging
    • 4.4.4.1. Packaging Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.4.5. Finished Dose Formulations
    • 4.4.5.1. Finished Dose Formulations Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.5.2. Solid
      • 4.4.5.2.1. Solid Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.5.3. Liquid
      • 4.4.5.3.1. Liquid Market Estimates and Forecasts, 2021 - 2033 (USD Million)
    • 4.4.5.4. Semi-solid Formulations
      • 4.4.5.4.1. Semi-solid Formulations Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 4.5. Research
  • 4.5.1. Research Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.2. Oncology
    • 4.5.2.1. Oncology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.3. Vaccines
    • 4.5.3.1. Vaccines Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.4. Inflammation & Immunology
    • 4.5.4.1. Inflammation & Immunology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.5. Cardiology
    • 4.5.5.1. Cardiology Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.6. Neuroscience
    • 4.5.6.1. Neuroscience Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 4.5.7. Others
    • 4.5.7.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 5. Pharmaceutical Contract Manufacturing And Research Services Market: Regional Estimates & Trend Analysis

• 5.1. Regional Market Dashboard
• 5.2. Regional Market Share Analysis, 2025 & 2033
• 5.3. North America
  • 5.3.1. North America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.3.2. U.S
    • 5.3.2.1. Key Country Dynamics
    • 5.3.2.2. Competitive Scenario
    • 5.3.2.3. Regulatory Framework
    • 5.3.2.4. U.S. Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.3.3. Canada
    • 5.3.3.1. Key Country Dynamics
    • 5.3.3.2. Competitive Scenario
    • 5.3.3.3. Regulatory Framework
    • 5.3.3.4. Canada Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.3.4. Mexico
    • 5.3.4.1. Key Country Dynamics
    • 5.3.4.2. Competitive Scenario
    • 5.3.4.3. Regulatory Framework
    • 5.3.4.4. Mexico Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.4. Europe
  • 5.4.1. Europe Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.2. UK
    • 5.4.2.1. Key Country Dynamics
    • 5.4.2.2. Competitive Scenario
    • 5.4.2.3. Regulatory Framework
    • 5.4.2.4. UK Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.3. Germany
    • 5.4.3.1. Key Country Dynamics
    • 5.4.3.2. Competitive Scenario
    • 5.4.3.3. Regulatory Framework
    • 5.4.3.4. Germany Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.4. France
    • 5.4.4.1. Key Country Dynamics
    • 5.4.4.2. Competitive Scenario
    • 5.4.4.3. Regulatory Framework
    • 5.4.4.4. France Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.5. Italy
    • 5.4.5.1. Key Country Dynamics
    • 5.4.5.2. Competitive Scenario
    • 5.4.5.3. Regulatory Framework
    • 5.4.5.4. Italy Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.6. Spain
    • 5.4.6.1. Key Country Dynamics
    • 5.4.6.2. Competitive Scenario
    • 5.4.6.3. Regulatory Framework
    • 5.4.6.4. Spain Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.7. Denmark
    • 5.4.7.1. Key Country Dynamics
    • 5.4.7.2. Competitive Scenario
    • 5.4.7.3. Regulatory Framework
    • 5.4.7.4. Denmark Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.8. Sweden
    • 5.4.8.1. Key Country Dynamics
    • 5.4.8.2. Competitive Scenario
    • 5.4.8.3. Regulatory Framework
    • 5.4.8.4. Sweden Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.4.9. Norway
    • 5.4.9.1. Key Country Dynamics
    • 5.4.9.2. Competitive Scenario
    • 5.4.9.3. Regulatory Framework
    • 5.4.9.4. Norway Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.5. Asia Pacific
  • 5.5.1. Asia Pacific Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.2. Japan
    • 5.5.2.1. Key Country Dynamics
    • 5.5.2.2. Competitive Scenario
    • 5.5.2.3. Regulatory Framework
    • 5.5.2.4. Japan Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.3. China
    • 5.5.3.1. Key Country Dynamics
    • 5.5.3.2. Competitive Scenario
    • 5.5.3.3. Regulatory Framework
    • 5.5.3.4. China Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.4. India
    • 5.5.4.1. Key Country Dynamics
    • 5.5.4.2. Competitive Scenario
    • 5.5.4.3. Regulatory Framework
    • 5.5.4.4. India Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.5. Australia
    • 5.5.5.1. Key Country Dynamics
    • 5.5.5.2. Competitive Scenario
    • 5.5.5.3. Regulatory Framework
    • 5.5.5.4. Australia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.6. Thailand
    • 5.5.6.1. Key Country Dynamics
    • 5.5.6.2. Competitive Scenario
    • 5.5.6.3. Regulatory Framework
    • 5.5.6.4. Thailand Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.5.7. South Korea
    • 5.5.7.1. Key Country Dynamics
    • 5.5.7.2. Competitive Scenario
    • 5.5.7.3. Regulatory Framework
    • 5.5.7.4. South Korea Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.6. Latin America
  • 5.6.1. Latin America Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6.2. Brazil
    • 5.6.2.1. Key Country Dynamics
    • 5.6.2.2. Competitive Scenario
    • 5.6.2.3. Regulatory Framework
    • 5.6.2.4. Brazil Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.6.3. Argentina
    • 5.6.3.1. Key Country Dynamics
    • 5.6.3.2. Competitive Scenario
    • 5.6.3.3. Regulatory Framework
    • 5.6.3.4. Argentina Market Estimates and Forecasts, 2021 - 2033 (USD Million)
• 5.7. MEA
  • 5.7.1. MEA Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7.2. South Africa
    • 5.7.2.1. Key Country Dynamics
    • 5.7.2.2. Competitive Scenario
    • 5.7.2.3. Regulatory Framework
    • 5.7.2.4. South Africa Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7.3. UAE
    • 5.7.3.1. Key Country Dynamics
    • 5.7.3.2. Competitive Scenario
    • 5.7.3.3. Regulatory Framework
    • 5.7.3.4. UAE Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7.4. Saudi Arabia
    • 5.7.4.1. Key Country Dynamics
    • 5.7.4.2. Competitive Scenario
    • 5.7.4.3. Regulatory Framework
    • 5.7.4.4. Saudi Arabia Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7.5. Kuwait
    • 5.7.5.1. Key Country Dynamics
    • 5.7.5.2. Competitive Scenario
    • 5.7.5.3. Regulatory Framework
    • 5.7.5.4. Kuwait Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7.6. Qatar
    • 5.7.6.1. Key Country Dynamics
    • 5.7.6.2. Competitive Scenario
    • 5.7.6.3. Regulatory Framework
    • 5.7.6.4. Qatar Market Estimates and Forecasts, 2021 - 2033 (USD Million)
  • 5.7.7. Oman
    • 5.7.7.1. Key Country Dynamics
    • 5.7.7.2. Competitive Scenario
    • 5.7.7.3. Regulatory Framework
    • 5.7.7.4. Oman Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 6. Competitive Landscape

• 6.1. Key Participant Categorization
  • 6.1.1. Market Leaders
  • 6.1.2. Emerging Players
• 6.2. Market Share/Assessment Analysis, 2025 (Heat Map Analysis)
• 6.3. Company Profiles
  • 6.3.1. Catalent, Inc. (Novo Holdings A/S)
    • 6.3.1.1. Company Overview
    • 6.3.1.2. Financial Performance
    • 6.3.1.3. Service Benchmarking
    • 6.3.1.4. Strategic Initiatives
  • 6.3.2. PPD (Thermo Fisher Scientific Inc.)
    • 6.3.2.1. Company Overview
    • 6.3.2.2. Financial Performance
    • 6.3.2.3. Service Benchmarking
    • 6.3.2.4. Strategic Initiatives
  • 6.3.3. AbbVie Inc.
    • 6.3.3.1. Company Overview
    • 6.3.3.2. Financial Performance
    • 6.3.3.3. Service Benchmarking
    • 6.3.3.4. Strategic Initiatives
  • 6.3.4. Advent International, L.P.
    • 6.3.4.1. Company Overview
    • 6.3.4.2. Financial Performance
    • 6.3.4.3. Service Benchmarking
    • 6.3.4.4. Strategic Initiatives
  • 6.3.5. Grifols
    • 6.3.5.1. Company Overview
    • 6.3.5.2. Financial Performance
    • 6.3.5.3. Service Benchmarking
    • 6.3.5.4. Strategic Initiatives
  • 6.3.6. Dalton Pharma Services
    • 6.3.6.1. Company Overview
    • 6.3.6.2. Financial Performance
    • 6.3.6.3. Service Benchmarking
    • 6.3.6.4. Strategic Initiatives
  • 6.3.7. Lonza
    • 6.3.7.1. Company Overview
    • 6.3.7.2. Financial Performance
    • 6.3.7.3. Service Benchmarking
    • 6.3.7.4. Strategic Initiatives
  • 6.3.8. Boehringer Ingelheim International GmbH
    • 6.3.8.1. Company Overview
    • 6.3.8.2. Financial Performance
    • 6.3.8.3. Service Benchmarking
    • 6.3.8.4. Strategic Initiatives